Abbott Laboratories (ABT) Debt to Equity (2009 - 2026)

Abbott Laboratories has disclosed Debt to Equity across 18 years of filings, most recently posting $0.65 for Q1 2026.

• Debt to Equity for Q1 2026 came in at $0.65, up 135.65% year-over-year; the trailing twelve-month figure through Mar 2026 was $0.65 (up 135.65% YoY), and the FY2025 annual result was $0.25, down 99.64% from the prior year.
• Debt to Equity came in at $0.65 for Q1 2026 at Abbott Laboratories, up from $0.25 in the prior quarter.
• In the past five years, Debt to Equity ranged from a high of $358.02 in Q4 2023 to a low of -$624.12 in Q3 2024.
• The 5-year median for Debt to Equity is $0.28 (2025), against an average of $5.69.
• Across the five-year window, Debt to Equity soared 52642.05% in 2023 and sank 33984.11% in 2024, its largest moves.
• Abbott Laboratories' Debt to Equity stood at $0.68 in 2022, then jumped by 52642.05% to $358.02 in 2023, then slumped by 81.21% to $67.26 in 2024, then tumbled by 99.64% to $0.25 in 2025, then jumped by 166.93% to $0.65 in 2026.
• The last three Debt to Equity figures came in at $0.65 (Q1 2026), $0.25 (Q4 2025), and $0.25 (Q3 2025), per Business Quant data.